Deals Of The Week: Merck/Calibr, GSK/Epistem, Biogen Idec/MAKScientific
Executive Summary
Shire addresses its Replagal disappointment with the acquisition of FerroKin and its hematology pipeline.
You may also be interested in...
Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated
Distributed free of charge to U.S. patients with Genzyme’s Fabrazyme in short supply, Replagal seemed destined for quick approval, but FDA has signalled otherwise.
FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones
FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
Prestige Brands acquires GlaxoSmithKline’s BC and Goody’s analgesic brands as part of $660 million deal for 17 North American OTC lines, also including Beano gas treatment, FiberChoice supplement and Sominex sleep aid.